Disparity in the process and outcome of the treatment for acute myocardial infarction in Japan: CAMPAIGN Study in the National Hospital Network

Circulation Journal

Volumn 69, Issue 12, 2005, Pages 1447-1453

  Kusuoka, Hideo ^a   Koretsune, Yukihiro ^a   Chino, Masao ^b   Nishiyama, Keiji ^c   Shiraki, Teruo ^d   Nakamura, Kazuhiko ^e   Inoue, Michitoshi ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c National Hospital Organization   (Japan)

^d IWAKUNI NATIONAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

Author keywords

Acute myocardial infarction; Japan; Outcome; Process

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT; NICORANDIL; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEALTH CARE SURVEYS; HOSPITAL MORTALITY; HUMANS; JAPAN; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRATES; PRESCRIPTIONS, DRUG; REGISTRIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 28544437882     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1447     Document Type: Article

References (25)

1. Quality of Care and Outcome Research in CVD and Stroke Working Groups. Measuring and Improving Quality of Care: A report from the American Heart Association/American College of Cardiology first scientific forum on assessment of healthcare quality in cardiovascular disease and stroke. Circulation 2000; 101: 1483 - 1493.
2. Spertus JA, Radford MJ, Every NR, Ellerbeck EF, Peterson ED, Krumholz HM. Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: Summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology first scientific forum on quality of care and outcome research in cardiovascular disease and stroke. Circulation 2003; 107: 1681 - 1691.
3. Kusuoka H, Koretsune Y, Inoue M. The disparity in the process and outcome of the treatment for acute myocardial infarction in Japan: Campaign study in the national hospital network. Circulation 2005; 111: e330 - e331.
4. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, van Natra P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) Trial. Circulation 1987; 75: 817 - 829.
5. Kinjo K, Sato H, Shiotani I, Kurotobi T, Ohnishi Y, Hishida E, et al. The Osaka Acute Coronary Insufficiency Study (OACIS) Group. Circadian variation of the onset of acute myocardial infarction in the Osaka area, 1998 - 1999. Jpn Circ J 2001; 65: 617 - 620.
6. Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every NR, for the Investigators in the National Registry of Myocardial Infarction 2#. Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. J Am Coll Cardiol 2000; 35: 371 - 379.
7. Casale PN, Jones JL, Wolf FE, Pei Y, Eby LM. Patients treated by cardiologists have a lower in-hospital mortality for acute myocardial infarction. J Am Coll Cardiol 1998; 32: 885 - 889.
8. Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104: 2171 - 2176.
9. Nanto S, Nagata M, Hori S, Sato H, Sato H, The Osaka Acute Coronary Insufficiency Study (OACIS) Group. Is in-hospital mortality rate for acute myocardial infarction related to number of in-patients? Jpn J Interv Cardiol 2001; 16(Suppl I): 142.
10. Tsuchihashi M, Tsutsui H, Tada H, Shihara M, Takeshita A, Kono S, and the Japanese Coronary Intervention Study (JCIS) Group. Volume - outcome relation for hospitals performing angioplasty for acute myocardial infarction. Circ J 2004; 68: 887 - 891.
11. Watanabe K, Nagao K, Watanabe I, Kanmatsuse K. Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction. Circ J 2004; 68: 280 - 285.
12. Kinoshita M, Ishikawa K, Inoue H, Kambara H, Kanmatsuse K, Saito Y, et al. Guidelines for secondary prevention of myocardial infarction. Jpn Circ J 2000; 64(Suppl IV): 1081 - 1127 (in Japanese).
13. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown-EJ Jr, Cuddy TE. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669 - 677.
14. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821 - 828.
15. Koeber L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670 - 1676.
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular eject fraction. N Engl J Med 1992; 327: 685 - 691.
17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335 - 371.
18. Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R, and The European Secondary Prevention Study Group. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction: Towards an understanding of factors influencing clinical practice. Eur Heart J 1998; 19: 74 - 79.
19. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of• -blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280: 623 - 629.
20. Avanzini F, Zuanetti G, Latini R, Colombo F, Santoro E, Maggioni AP, on behalf of the Gruppo Italiano di Studio sulla Sopravvivenza nell' Infarto Miocardico (GISSI) Investigators. Use of beta-blocking agents in secondary prevention after myocardial infarction: A case for evidence-based medicine? GISSI experience, 1984 - 1993. Eur Heart J 1997; 18: 1447 - 1456.
21. Hjalmarson A. effects of beta blockade on sudden cardiac death dur-ing acute myocardial infarction and the postinfarction period. Am J Cardiol 1997; 80(9B): 35J - 39J.
22. Sleight P. Professor Peter Sleight's reflections on the use of• -blocking agents after myocardial infarction. Am Heart J 1997; 134(Suppl): S15- S20.
23. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with• -blockers: Importance of ancillary properties. Prog Cardiovasc Dis 1997; 39: 445 - 456.
24. Antman EM, Kuntz KM. The length of the hospital stay after myocardial infarction. N Engl J Med 2000; 342: 808 - 810.
25. Alter DA, Naylor CD, Austin PC, Tu JV. Long-term MI outcomes at hospitals with or without on-site revascularization. JAMA 2001; 285: 2101 - 2108.